<?xml version="1.0"?><rdf:RDF xmlns:dc="http://purl.org/dc/elements/1.1/" xmlns:edm="http://www.europeana.eu/schemas/edm/" xmlns:wgs84_pos="http://www.w3.org/2003/01/geo/wgs84_pos" xmlns:foaf="http://xmlns.com/foaf/0.1/" xmlns:rdaGr2="http://rdvocab.info/ElementsGr2" xmlns:oai="http://www.openarchives.org/OAI/2.0/" xmlns:owl="http://www.w3.org/2002/07/owl#" xmlns:rdf="http://www.w3.org/1999/02/22-rdf-syntax-ns#" xmlns:ore="http://www.openarchives.org/ore/terms/" xmlns:skos="http://www.w3.org/2004/02/skos/core#" xmlns:dcterms="http://purl.org/dc/terms/"><edm:WebResource rdf:about="http://www.dlib.si/stream/URN:NBN:SI:DOC-ZZ6C63YS/a963d6f7-b6ae-41c5-ab61-d133a15050dd/PDF"><dcterms:extent>379 KB</dcterms:extent></edm:WebResource><edm:WebResource rdf:about="http://www.dlib.si/stream/URN:NBN:SI:DOC-ZZ6C63YS/3d29606b-4076-4e8d-86bb-95e28fa96875/TEXT"><dcterms:extent>29 KB</dcterms:extent></edm:WebResource><edm:TimeSpan rdf:about="2022-2025"><edm:begin xml:lang="en">2022</edm:begin><edm:end xml:lang="en">2025</edm:end></edm:TimeSpan><edm:ProvidedCHO rdf:about="URN:NBN:SI:DOC-ZZ6C63YS"><dcterms:isPartOf rdf:resource="https://www.dlib.si/details/URN:NBN:SI:spr-UCB4A42Q" /><dcterms:issued>2025</dcterms:issued><dc:creator>Prestreši, Leonora</dc:creator><dc:format xml:lang="sl">številka:4</dc:format><dc:format xml:lang="sl">str. 46-50</dc:format><dc:identifier>COBISSID_HOST:248507395</dc:identifier><dc:identifier>ISSN:2820-5014</dc:identifier><dc:identifier>URN:URN:NBN:SI:doc-ZZ6C63YS</dc:identifier><dc:language>sl</dc:language><dc:publisher xml:lang="sl">Fakulteta za farmacijo, ŠSSFD</dc:publisher><dcterms:isPartOf xml:lang="sl">Placebo</dcterms:isPartOf><dc:subject xml:lang="en">cannabidiol</dc:subject><dc:subject xml:lang="en">cannabinoids</dc:subject><dc:subject xml:lang="sl">CBD</dc:subject><dc:subject xml:lang="en">endocannabinoid system</dc:subject><dc:subject xml:lang="sl">endokanabinoidni sistem</dc:subject><dc:subject xml:lang="en">inflammation</dc:subject><dc:subject xml:lang="sl">kanabidiol</dc:subject><dc:subject xml:lang="sl">Kanabinoidi</dc:subject><dc:subject xml:lang="sl">Luskavica</dc:subject><dc:subject xml:lang="en">psoriasis</dc:subject><dc:subject xml:lang="sl">vnetje</dc:subject><dcterms:temporal rdf:resource="2022-2025" /><dc:title xml:lang="sl">Kanabinoidi v terapiji luskavice| različni pristopi zdravljenja dermatoveneroloških bolezni|</dc:title><dc:description xml:lang="sl">Cannabinoids are compounds that influence various physiological processes in the body through the endocannabinoid system (ECS). This system plays a crucial role in regulating inflammation, immune responses, oxidative stress, and skin homeostasis. In recent years, cannabinoids have emerged as a promising topic of research, including in the treatment of psoriasis — a chronic inflammatory skin disease with a complex immunological background. Psoriasis is characterized by excessive keratinocyte proliferation, inflammation, and angiogenesis, involving numerous inflammatory cytokines and growth factors. Cannabidiol (CBD), a non-psychoactive compound derived from Cannabis sativa, has gained particular attention due to its multifaceted therapeutic potential. Studies have shown that CBD may reduce inflammation, oxidative stress, itching, and abnormal keratinocyte proliferation, while improving skin hydration. Promising results have also been observed with synthetic cannabinoids such as JWH-133, which exhibit anti-inflammatory and anti-angiogenic properties. Despite encouraging findings, further studies are necessary to confirm the efficacy and safety of cannabinoids in psoriasis treatment</dc:description><dc:description xml:lang="sl">Kanabinoidi so spojine, ki vplivajo na različne fiziološke procese v telesu prek endokanabinoidnega sistema (EKS). Ta sistem ima pomembno vlogo pri uravnavanju vnetja, imunskega odziva, oksidativnega stresa in homeostaze kože. V zadnjih letih postajajo kanabinoidi zanimiva tema raziskav, tudi na področju zdravljenja luskavice – kronične vnetne kožne bolezni z zapletenim imunološkim ozadjem. Pri luskavici pride do prekomerne delitve kožnih celic, vnetja in povečane tvorbe krvnih žil, pri čemer sodelujejo številni vnetni citokini in rastni faktorji. Posebno pozornost je pritegnil kanabidiol (CBD), nepsihoaktivna sestavina rastline Cannabis sativa, ki kaže večplasten terapevtski potencial. Študije so pokazale, da lahko CBD zmanjša vnetje, oksidativni stres, srbenje in prekomerno razmnoževanje keratinocitov, obenem pa izboljša hidracijo kože. Obetavne rezultate kažejo tudi nekateri sintetični kanabinoidi, kot je JWH-133, ki delujejo protivnetno in antiangiogeno. Kljub spodbudnim ugotovitvam so za potrditev učinkovitosti in varnosti potrebne dodatne raziskave</dc:description><edm:type>TEXT</edm:type><dc:type xml:lang="sl">znanstveno časopisje</dc:type><dc:type xml:lang="en">journals</dc:type><dc:type rdf:resource="http://www.wikidata.org/entity/Q361785" /></edm:ProvidedCHO><ore:Aggregation rdf:about="http://www.dlib.si/?URN=URN:NBN:SI:DOC-ZZ6C63YS"><edm:aggregatedCHO rdf:resource="URN:NBN:SI:DOC-ZZ6C63YS" /><edm:isShownBy rdf:resource="http://www.dlib.si/stream/URN:NBN:SI:DOC-ZZ6C63YS/a963d6f7-b6ae-41c5-ab61-d133a15050dd/PDF" /><edm:rights rdf:resource="http://rightsstatements.org/vocab/InC/1.0/" /><edm:provider>Slovenian National E-content Aggregator</edm:provider><edm:dataProvider xml:lang="en">National and University Library of Slovenia</edm:dataProvider><edm:object rdf:resource="http://www.dlib.si/streamdb/URN:NBN:SI:DOC-ZZ6C63YS/maxi/edm" /><edm:isShownAt rdf:resource="http://www.dlib.si/details/URN:NBN:SI:DOC-ZZ6C63YS" /></ore:Aggregation></rdf:RDF>